论文部分内容阅读
２１例晚期肺癌病人接受紫杉醇治疗。临床分期ⅢＢ１０例，Ⅳ１１例。化疗方案采用单药紫杉醇组９例，紫杉醇联合应用－ＤＤＰ－ＶＰ１６组１２例，总计３６个疗程。化疗后达ＣＲ１例，ＰＲ４例，ＭＲ４例，有效率２３．８％。紫杉醇的不良反应主要为粒细胞减少２０例次，其中Ⅲ度以上９例次，多为联合用药组，一般发生于用药后ｄ７～８，ｄ１０达最低值，２１ｄ均恢复正常。用Ｇ－ＣＳＦ能减轻粒细胞下降程度。经预防应用抗过敏药物后，无１例发生严重高敏反应。脱发见于每例病人，肌肉关节痛２７例次（７５％）．本药适用于非小细胞肺癌及复发性小细胞肺癌，联合应用其他有效的化疗药物有可能进一步改善反应率
Twenty-one patients with advanced lung cancer received paclitaxel. Clinical stage Ⅲ B10 cases, Ⅳ 11 cases. Chemotherapy regimen used single-agent paclitaxel group 9 cases, paclitaxel combined -DDP-VP16 group 12 cases, a total of 36 courses. Up to CR1 after chemotherapy, PR4 cases, MR4 cases, the effective rate of 23.8%. Adverse reactions of paclitaxel were mainly 20 cases of neutropenia, of which more than Ⅲ degrees and 9 cases were mostly combination therapy group, which usually occurred after treatment d7 ~ 8, d10 reached the lowest value, returned to normal after 21 days. G-CSF can reduce the degree of neutropenia. After preventing the application of anti-allergic drugs, no case of severe hypersensitivity. Hair loss seen in each patient, muscle and joint pain in 27 cases (75%). The drug is suitable for non-small cell lung cancer and recurrent small cell lung cancer, combined with other effective chemotherapy drugs may further improve the response rate